drugset
drugset / Trial / NCT05098275

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

NCT05098275 ↗

Phase 1 Completed 38 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

Phamacokinetics and safety profiles of DA-5210 10/500mg in Healthy subjects at Fed State

Timeline

Start
2021-10-26
Primary completion
2022-02-06
Completion
2022-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-5210 Unknown 10 mg —
Subject DA-5210 Unknown 500 mg —
Subject DA-5210-R Unknown 10 mg —
Subject DA-5210-R Unknown 500 mg —

Indications

No indication recorded.